Literature DB >> 12193460

Innate and adaptive immunity in the pathogenesis of atherosclerosis.

Göran K Hansson1, Peter Libby, Uwe Schönbeck, Zhong-Qun Yan.   

Abstract

This review considers critically the evidence for the involvement of mediators of innate and acquired immunity in various stages of atherosclerosis. Rapidly mobilized arms of innate immunity, including phagocytic leukocytes, complement, and proinflammatory cytokines, contribute to atherogenesis. In addition, adaptive immunity, with its T cells, antibodies, and immunoregulatory cytokines, powerfully modulates disease activity and progression. Atherogenesis involves cross talk between and shared pathways involved in adaptive and innate immunity. Immune processes can influence the balance between cell proliferation and death, between synthetic and degradative processes, and between pro- and antithrombotic processes. Various established and emerging risk factors for atherosclerosis modulate aspects of immune responses, including lipoproteins and their modified products, vasoactive peptides, and infectious agents. As we fill in the molecular details, new potential targets for therapies will doubtless emerge.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12193460     DOI: 10.1161/01.res.0000029784.15893.10

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  224 in total

1.  Time course of transcardiac interleukin-6 release after coronary stenting for stable angina.

Authors:  J M Kefer; L M Galanti; C E Hanet
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

2.  IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis.

Authors:  Christoph J Binder; Karsten Hartvigsen; Mi-Kyung Chang; Marina Miller; David Broide; Wulf Palinski; Linda K Curtiss; Maripat Corr; Joseph L Witztum
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

3.  Marked acceleration of atherosclerosis after Lactobacillus casei-induced coronary arteritis in a mouse model of Kawasaki disease.

Authors:  Shuang Chen; Youngho Lee; Timothy R Crother; Michael Fishbein; Wenxuan Zhang; Atilla Yilmaz; Kenichi Shimada; Danica J Schulte; Thomas J A Lehman; Prediman K Shah; Moshe Arditi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-05-24       Impact factor: 8.311

4.  Albumin-based microbubbles bind up-regulated scavenger receptors following vascular injury.

Authors:  Daniel R Anderson; Michael J Duryee; Rajeev K Anchan; Robert P Garvin; Michael D Johnston; Thomas R Porter; Geoffrey M Thiele; Lynell W Klassen
Journal:  J Biol Chem       Date:  2010-10-21       Impact factor: 5.157

5.  EGCG prevents PCB-126-induced endothelial cell inflammation via epigenetic modifications of NF-κB target genes in human endothelial cells.

Authors:  Dandan Liu; Jordan T Perkins; Bernhard Hennig
Journal:  J Nutr Biochem       Date:  2015-10-26       Impact factor: 6.048

Review 6.  Atherosclerotic vascular disease in the autoimmune rheumatologic patient.

Authors:  Rekha Mankad
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

7.  Coronary intraplaque hemorrhage evokes a novel atheroprotective macrophage phenotype.

Authors:  Joseph J Boyle; Heather A Harrington; Emma Piper; Kay Elderfield; Jaroslav Stark; Robert C Landis; Dorian O Haskard
Journal:  Am J Pathol       Date:  2009-03       Impact factor: 4.307

8.  Hydrogen sulfide suppresses oxidized low-density lipoprotein (ox-LDL)-stimulated monocyte chemoattractant protein 1 generation from macrophages via the nuclear factor κB (NF-κB) pathway.

Authors:  Junbao Du; Yaqian Huang; Hui Yan; Qiaoli Zhang; Manman Zhao; Mingzhu Zhu; Jia Liu; Stella X Chen; Dingfang Bu; Chaoshu Tang; Hongfang Jin
Journal:  J Biol Chem       Date:  2014-02-18       Impact factor: 5.157

9.  Helicobacter pylori vs coronary heart disease - searching for connections.

Authors:  Magdalena Chmiela; Adrian Gajewski; Karolina Rudnicka
Journal:  World J Cardiol       Date:  2015-04-26

10.  Biochemical markers for cardiovascular risk following treatment in endogenous Cushing's syndrome.

Authors:  C Kristo; T Ueland; K Godang; P Aukrust; J Bollerslev
Journal:  J Endocrinol Invest       Date:  2008-05       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.